-
公开(公告)号：US10233229B2
公开(公告)日：2019-03-19
申请号：US14650188
申请日：2013-11-25
Applicant: Pfizer Inc.
Inventor： Tetsuya Ishino , Weili Duan , Ronald William Kriz
Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
-
2.发明申请公开(公告)号：US20180052175A1
公开(公告)日：2018-02-22
申请号：US15601617
申请日：2017-05-22
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
Patent Agency Ranking
3.发明授权公开(公告)号：US11474112B2
公开(公告)日：2022-10-18
申请号：US16422256
申请日：2019-05-24
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
4.发明授权公开(公告)号：US09683998B2
公开(公告)日：2017-06-20
申请号：US14539845
申请日：2014-11-12
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Madar , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor-like ligand 1A (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
公开(公告)号：US20150322135A1
公开(公告)日：2015-11-12
申请号：US14650188
申请日：2013-11-25
Applicant: PFIZER INC.
Inventor： Tetsuya Ishino , Weili Duan , Ronald William Kriz
IPC: C07K16/00
CPC classification number: C07K16/00 , C07K2299/00 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/64 , C07K2317/94
Abstract: The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
Abstract translation: 本发明涉及包含工程化单体抗体片段（例如含单体Fc的多肽）的单体多肽，其中单体Fc包含在CH3-CH3二聚化界面中的一个或多个工程化的N-连接的糖基化位点。 还提供了生产这种工程化单体抗体片段的方法及其在诊断和治疗中的应用。
-
6.发明申请公开(公告)号：US20190331694A1
公开(公告)日：2019-10-31
申请号：US16422256
申请日：2019-05-24
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
-
7.发明申请TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF 有权肿瘤坏死因子类似配体1A特异性抗体及其组合物及其用途公开(公告)号：US20150132311A1
公开(公告)日：2015-05-14
申请号：US14539845
申请日：2014-11-12
Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
Inventor： Robert Arch , Jun Zhang , Michelle Madar , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
CPC classification number: G01N33/6863 , C07K16/2875 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Abstract translation: 本发明提供特异性结合TL1A的抗体或其抗原结合片段。 本发明还提供了获得这样的抗体的方法和编码该抗体的核酸。 本发明还涉及使用这些抗体治疗和/或预防TL1A介导的疾病，病症或病症的组合物和治疗方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.029 seconds)
